Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 22, Issue 8, Pages 1178-1182Publisher
WILEY
DOI: 10.1111/j.1440-1746.2007.04997.x
Keywords
angiogenesis; hepatocarcinogenesis; hepatocellular carcinoma; hypoxia induced factor-1; hypoxia; metastasis
Categories
Ask authors/readers for more resources
Hypoxia enhances proliferation, angiogenesis, metastasis, chemoresistance, and radioresistance of hepatocellular carcinoma (HCC); suppresses differentiation and apoptosis of HCC; and consequently leads to resistance of transarterial embolization (with or without chemotherapy). Because transarterial embolization contributes to angiogenesis via inducing hypoxia, therapy combined with transarterial embolization and antiangiogenic therapy provides a new strategy for the treatment of HCC. Unfortunately, hypoxia leads to the escape of HCC cells from transarterial embolization and antiangiogenic therapy. Thus combined therapy that induces and targets hypoxia may be of benefit to HCC patients. Because angiogenesis plays an important role in recurrence of HCC after resection, antiangiogenic therapy is beneficial to HCC patients following surgical resection of the tumor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available